HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Angiodysplasia of gastrointestinal tract — Clinical Guidelines

Overview

Angiodysplasia of the gastrointestinal tract refers to abnormal blood vessel formations that can lead to chronic bleeding, often affecting the small intestine and colon, and is associated with conditions like aortic valve disease and antiphospholipid syndrome. 1 5

Diagnosis

Endoscopic visualization and confirmation via angiography 1 5

Consider evaluation for von Willebrand syndrome type 2A, especially in patients with cardiovascular disease 2

Upper and lower gastrointestinal tract examination recommended due to potential spatial clustering 4

Management

First-line treatments: Endoscopic interventions (e.g., coagulation) for localized bleeding sites 1 5

Adjunctive therapies:

- Hormonal therapy (ethinylestradiol 0.01 mg + norethisterone 2 mg daily) showed no significant benefit in preventing rebleeding 3 - Systemic bevacizumab for severe, refractory cases, particularly in patients requiring indefinite anticoagulation 1

Special Populations

Elderly: Higher incidence of bleeding GI angiodysplasia linked to cardiovascular disease and acquired von Willebrand syndrome 2

Comorbidities: Patients with aortic valve disease may have a higher risk of upper gastrointestinal angiodysplasia 5

Key Recommendations

Evaluate for von Willebrand syndrome type 2A in patients with cardiovascular disease and gastrointestinal angiodysplasia to guide management 2 (Evidence: Moderate)

Consider endoscopic interventions as first-line treatment for localized bleeding sites 1 5 (Evidence: Expert opinion)

Systemic bevacizumab may be effective in managing severe, refractory bleeding cases requiring indefinite anticoagulation, though its use should be individualized 1 (Evidence: Weak)

Conduct comprehensive endoscopic examinations of both upper and lower gastrointestinal tracts due to potential spatial clustering of angiodysplasias 4 (Evidence: Moderate)

References

1 Cheloff AZ, Song AB, D'Silva KM, Al-Samkari H. Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia. Journal of thrombosis and thrombolysis 2022. link 2 Warkentin TE, Moore JC, Anand SS, Lonn EM, Morgan DG. Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfusion medicine reviews 2003. link00037-3) 3 Junquera F, Feu F, Papo M, Videla S, Armengol JR, Bordas JM et al.. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001. link 4 Cappell MS. Spatial clustering of simultaneous nonhereditary gastrointestinal angiodysplasia. Small but significant correlation between nonhereditary colonic and upper gastrointestinal angiodysplasia. Digestive diseases and sciences 1992. link 5 Weaver GA, Alpern HD, Davis JS, Ramsey WH, Reichelderfer M. Gastrointestinal angiodysplasia associated with aortic valve disease: part of a spectrum of angiodysplasia of the gut. Gastroenterology 1979. link

Angiodysplasia of gastrointestinal tract